Bellus Health Inc.

Biochem Pharma Inc.

Bhi Limited Partnership

Merck Sharp + Dohme Corp.

Msd Italia S.r.l.

Merck Canada Inc.

Benoit Bachand

Sophie Levesque

Xianqi Kong

Daniel Delorme

Abderrahim Bouzide

David Migneault

Xinfu Wu

Isabelle Valade

Mohamed Atfani

Stephane Ciblat

Nghe Nguyen-Ba

Francine Gervais

Arshad Siddiqui

Bita Samim

Nigel J Liverton

Samuel Chackalamannil

Yongxin Han

John A McCauley

Srikanth Venkatraman

Michael T Rudd

John W Gillard

Vincenzo Summa

Marco Ferrara

Annette Marian Doherty

Jeremy John Edmunds

Francisco Velazquez

Steven Harper

Unmesh G Shah

John DiMaio

Helmi Zaghdane

M Arshad Siddiqui

Yves St-Denis

Stéphane Ciblat

Virender Singh Aulakh

Patrick Beaulieu

Sylvie Charron

Marie-Christine Brochu

Christiane Grisé-Bard

Patrice Preville

Micheline Tarazi

Marie-Christine Brouchu

John Mccauley

Unmesh Shah

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease.

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections. 

HCV NS3 protease inhibitors

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Method and compositions for treating amyloid-related diseases

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.

Methods and compositions for treating amyloid-related diseases

The present invention is concerned with novel &lsqb;1,8&rsqb; naphthyridine derivatives useful for the inhibition of the hepatitis virus, more specifically the hepatitis C virus.

&lsqb;1,8&rsqb; naphthyridine derivatives having antiviral activity

Antiviral methods using &lsqb;1,8&rsqb;naphthyridine derivatives

This invention relates to the discovery of heterocyclic competitive inhibitors of the enzyme thrombin, their preparation, and pharmaceutical compositions thereof. As well, this invention relates to the use of such compounds and compositions in vitro as anticoagulants and in vivo as agents for the treatment and prophylaxis of thrombotic disorders such as venous thrombosis, pulmonary embolism and arterial thrombosis resulting in acute ischemic events such as myocardial infarction or cerebral infarction. Moreover, these compounds and compositions have therapeutic utility for the prevention and treatment of coagulopathies associated with coronary bypass operations as well as restenotic events following transluminal angioplasty.

Low molecular weight bicyclic thrombin inhibitors

Growing community of inventors

Saint-Laurent, Canada

Benoit Bachand